BN Business News
会社を追加 →
この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。

ビジネス · 2009/10/211 分で読めます

Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Cardiac Allograft Gene Expression Profiling Test Systems

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA) is announcing the classification of cardiac allograft gene expression profiling test systems into class II (special controls). The special control that will apply to the device is the guidance document entitled "Class II Special Controls Guidance Document: Cardiac Allograft Gene Expression Profiling Test Systems." FDA classified the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance document that will serve as the special control for this device.

情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →

関連インサイト

ビジネスインサイト →